Novel insights on the malignant transformation of endometriosis into ovarian carcinoma

Gynecological Endocrinology

Volumn 30, Issue 9, 2014, Pages 612-617

  Gadducci, Angiolo ^a   Lanfredini, Nora ^a   Tana, Roberta ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

ARID1A; Endometriosis; Ovarian clear cell carcinoma; Ovarian endometrioid carcinoma; PIK3CA; PTEN

Indexed keywords

ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR;

CANCER RISK; CLEAR CELL CARCINOMA; ENDOMETRIOSIS; FEMALE; GENE MUTATION; GYNECOLOGIC DISEASE; HUMAN; LEIOMYOMATOSIS PERITONEALIS DISSEMINATA; MALIGNANT TRANSFORMATION; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION; CARCINOMA; CELL TRANSFORMATION; COMPLICATION; OVARIAN NEOPLASMS;

CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIOSIS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84906260891     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.926325     Document Type: Review

References (76)

1. Olive DL, Schwartz LB. Endometriosis. N Engl J Med 1993; 328: 1759-69.
2. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecologic Oncol 2012; 124: 164-9.
3. Nishida M, Watanabe K, Sato N, Ichikawa Y. Malignant transformation of ovarian endometriosis. Gynecol Obstet Invest 2000; 50: 18-25.
4. Van Gorp T, Amant F, Neven P, et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004; 18: 349-71.
5. Brinton LA, Gridley G, Persson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997; 176: 572-9.
6. Melin A, Sparen P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 2006; 21: 1237-42.
7. Kobayashi H, Sumimoto K, Moniwa N, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 2007; 17: 37-43.
8. Rossing MA, Cushing-Haugen KL, Wicklund KG, et al. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control 2008; 19: 1357-64.
9. Gemmill JA, Stratton P, Cleary SD, et al. Cancers, infections, and endocrine diseases in women with endometriosis. Fertil Steril 2010; 94: 1627-31.
10. Buis CC, van Leeuwen FE, Mooij TM, Burger CW. OMEGA Project Group. Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod 2013; 28: 3358-69.
11. Heidemann LN, Hartwell D, Heidemann CH, Jochumsen KM. The relation between endometriosis and ovarian cancer - a review. Acta Obstet Gynecol Scand 2014; 93: 20-31.
12. McCluggage WG, Desai V, Toner PG, Calvert CH. Clear cell adenocarcinoma of the colon arising in endometriosis: a rare variant of primary colonic adenocarcinoma. J Clin Pathol 2001; 54: 76-7.
13. Min KW, Koh YW, Ryu YJ, et al. Primary clear cell adenocarcinoma arising from rectal endometriosis. Dig Endosc 2013; 25: 209-10.
14. Balat O, Kudelka AP, Edwards CL, et al. Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma. Eur J Gynaecol Oncol 1996; 17: 13-16.
15. Lah K, Desai D, Hadway P, et al. Primary vesical clear cell adenocarcinoma arising in endometriosis: a rare case of Mullerian origin. Anticancer Res 2013; 33: 615-17.
16. Kwon YS, Nam JH, Choi G. Clear cell adenocarcinoma arising in endometriosis of a previous episiotomy site. Obstet Gynecol 2008; 112: 475-7.
17. Shah C, Pizer E, Veljovich DS, et al. Clear cell adenocarcinoma of the vagina in a patient with vaginal endometriosis. Gynecol Oncol 2006; 103: 1130-2.
18. Bolis GB, Macciò T. Clear cell adenocarcinoma of the vulva arising in endometriosis. A case report. Eur J Gynaecol Oncol 2000; 21: 416-17.
19. Alberto VO, Lynch M, Labbei FN, Jeffers M. Primary abdominal wall clear cell carcinoma arising in a caesarean section scar endometriosis. Ir J Med Sci 2006; 175: 69-71.
20. Mert I, Semaan A, Kim S, et al. Clear cell carcinoma arising in the abdominal wall: two case reports and literature review. Am J Obstet Gynecol 2012; 207: e7-9.
21. Stevens EE, Pradhan TS, Chak Y, Lee YC. Malignant transformation of endometriosis in a cesarean section abdominal wall scar: a case report. J Reprod Med 2013; 58: 264-6.
22. Toriyama A, Ishida M, Amano T, et al. Leiomyomatosis peritonealis disseminata coexisting with endometriosis within the same lesions: a case report with review of the literature. Int J Clin Exp Pathol 2013; 6: 2949-54.
23. Al-Talib A, Tulandi T. Pathophysiology and possible iatrogenic cause of leiomyomatosis peritonealis disseminata. Gynecol Obstet Invest 2010; 69: 239-44.
24. Sharma P, Chaturvedi KU, Gupta R, Nigam S. Leiomyomatosis peritonealis disseminata with malignant change in a post-menopausal woman. Gynecol Oncol 2004; 95: 742-5.
25. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum Pathol 2011; 42: 918-31.
26. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012; 460: 237-49.
27. Erzen M, Rakar S, Klancnik B, Syrjänen K. Endometriosisassociated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 2001; 83: 100-8.
28. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155: 217-24.
29. Merritt MA, Green AC, Nagle CM, Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008; 122: 170-6.
30. Mandai M, Yamaguchi K, Matsumura N, et al. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 2009; 14: 383-91.
31. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13: 385-94.
32. Kim HS, Kim TH, Chung HH, Song YS. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 2014; 110: 1878-90.
33. Maeda D, Shih IeM. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 2013; 20: 45-52.
34. LaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Hum Pathol 1988; 19: 1080-4.
35. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997; 30: 249-55.
36. Clement PB. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Path 2007; 14: 241-60.
37. Czernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol 1978; 53: 318-23.
38. Moll UM, Chumas JC, Chalas E, Mann WJ. Ovarian carcinoma arising in atypical endometriosis. Obstet Gynecol 1990; 75: 537-9.
39. Seidman JD. Prognostic importance of hyperplasia and atypia in endometriosis. Int J Gynecol Pathol 1996; 15: 1-9.
40. Modesitt SC, Tortolaro-Luna G, Robinson JB, et al. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 2002; 100: 788-95.
41. Tanase Y, Furukawa N, Kobayashi H, Matsumoto T. Malignant transformation from endometriosis to atypical endometriosis and finally to endometrioid adenocarcinoma within 10 years. Case Rep Oncol 2013; 6: 480-4.
42. Catasús L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35: 1360-8.
43. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol Mech Dis 2009; 4: 287-313.
44. McConechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 2014; 27: 128-34.
45. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60: 7052-6.
46. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
47. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012; 22: 1310-15.
48. Stewart CJ, Walsh MD, Budgeon CA, et al. Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: correlation with KRAS mutation and the presence of endometriosis. Pathology 2013; 45: 559-66.
49. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-63.
50. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009; 28: 1653-68.
51. Liu J, Albarracin CT, Chang KH, et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol 2004; 17: 75-80.
52. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174: 1597-601.
53. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-31.
54. Yamamoto S, Tsuda H, Takano M, et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 2012; 25: 615-24.
55. Xiao W, Awadallah A, Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol 2012; 5: 642-50.
56. Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2012; 25: 282-8.
57. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch 2012; 460: 77-87.
58. Fujimura M, Hidaka T, Kataoka K, et al. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 2001; 25: 667-72.
59. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006; 19: 83-9.
60. Kobayashi H, Yamada Y, Kanayama S, et al. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009; 19: 471-9.
61. Cillo C, Faiella A, Cantile M, Boncinelli E. Homeobox genes and cancer. Exp Cell Res 1999; 248: 1-9.
62. Yamashita Y, Akatsuka S, Shinjo K, et al. Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. PLoS One 2013; 8: e57724.
63. Lacroix L, Post SF, Valent A, et al. MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One 2014; 9: e84319.
64. Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol 2010; 2010: 740968.
65. Samartzis EP, Samartzis N, Noske A, et al. Loss of ARID1A/ BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Mod Pathol 2012; 25: 885-92.
66. Wu RC, Ayhan A, Maeda D, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol 2014; 232: 473-81.
67. Wu CH, Mao TL, Vang R, et al. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol 2012; 31: 297-303.
68. Somigliana E, Vigano P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101: 331-41.
69. Van Langendonckt A, Casanas-Roux F, Donnez J. Iron overload in the peritoneal cavity of women with pelvic endometriosis. Fertil Steril 2002; 78: 712-18.
70. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009; 100: 9-16.
71. Jackson LW, Schisterman EF, Dey-Rao R, et al. Oxidative stress and endometriosis. Hum Reprod 2005; 20: 2014-20.
72. Ngô C, Chéreau C, Nicco C, et al. Reactive oxygen species controls endometriosis progression. Am J Pathol 2009; 175: 225-34.
73. Shigetomi H, Higashiura Y, Kajihara H, Kobayashi H. A potential link of oxidative stress and cell cycle regulation for development of endometriosis. Gynecol Endocrinol 2012; 28: 897-902.
74. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the ironinduced persistent oxidative stress. Clin Cancer Res 2008; 14: 32-40.
75. Vercellini P, Crosignani P, Somigliana E, et al. The 'incessant menstruation' hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum Reprod 2011; 26: 2262-73.
76. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010; 29: 1741-52.